BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

This study is currently recruiting participants. (see Contacts and Locations)
Verified June 2016 by M.D. Anderson Cancer Center
Sponsor:
Collaborators:
AstraZeneca
Bayer
Merck Sharp & Dohme Corp.
National Cancer Institute (NCI)
OSI Pharmaceuticals
Yale University
Information provided by (Responsible Party):
M.D. Anderson Cancer Center
ClinicalTrials.gov Identifier:
NCT01248247
First received: November 23, 2010
Last updated: June 21, 2016
Last verified: June 2016
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is currently recruiting participants.
  Estimated Study Completion Date: No date given
  Estimated Primary Completion Date: June 2018 (Final data collection date for primary outcome measure)